Griscelli syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:381OMIM:214450E70.3
Who is this for?
Show terms as
2Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Griscelli syndrome (GS) is a rare autosomal recessive disorder characterized by hypopigmentation of the skin and hair (silvery-gray hair) combined with variable immunological and neurological impairment. The condition results from defective melanosome transport, leading to characteristic large clumps of pigment in the hair shaft and an accumulation of melanosomes in melanocytes. Three subtypes have been identified based on the underlying genetic cause: GS type 1 (MYO5A gene) presents primarily with hypopigmentation and severe primary neurological impairment; GS type 2 (RAB27A gene) is the most common form and features hypopigmentation with a severe primary immunodeficiency leading to uncontrolled T-lymphocyte and macrophage activation, known as hemophagocytic lymphohistiocytosis (HLH); and GS type 3 (MLPH gene) presents with isolated hypopigmentation without immunological or neurological involvement. The syndrome primarily affects the immune system, the nervous system, and the integumentary system (skin and hair). GS type 2, the most clinically significant form, is characterized by recurrent and often life-threatening episodes of HLH, which manifests as fever, hepatosplenomegaly, pancytopenia, and multi-organ dysfunction. Without treatment, HLH episodes in GS type 2 are typically fatal in early childhood. GS type 1 is associated with severe neurological dysfunction including hypotonia, intellectual disability, and seizures. The only curative treatment for GS type 2 is hematopoietic stem cell transplantation (HSCT), which corrects the immunological defect but does not reverse the pigmentary dilution. Acute HLH episodes are managed with immunosuppressive and chemotherapeutic protocols. GS type 1 has no specific curative treatment, and management is supportive. GS type 3, being limited to hypopigmentation, generally has a benign course and requires no specific treatment. Early diagnosis through microscopic examination of hair shafts and genetic testing is critical for appropriate management, particularly to distinguish GS type 2 from other forms.

Also known as:

Clinical phenotype terms— hover any for plain English:

Abnormality of neutrophilsHP:0001874Pyloric stenosisHP:0002021
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Infantile

Begins in infancy, roughly 1 month to 2 years old

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Griscelli syndrome.

View clinical trials →

No actively recruiting trials found for Griscelli syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Griscelli syndrome community →

Specialists

2 foundView all specialists →

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Griscelli syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Griscelli syndromeForum →

No community posts yet. Be the first to share your experience with Griscelli syndrome.

Start the conversation →

Latest news about Griscelli syndrome

No recent news articles for Griscelli syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Griscelli syndrome

What is Griscelli syndrome?

Griscelli syndrome (GS) is a rare autosomal recessive disorder characterized by hypopigmentation of the skin and hair (silvery-gray hair) combined with variable immunological and neurological impairment. The condition results from defective melanosome transport, leading to characteristic large clumps of pigment in the hair shaft and an accumulation of melanosomes in melanocytes. Three subtypes have been identified based on the underlying genetic cause: GS type 1 (MYO5A gene) presents primarily with hypopigmentation and severe primary neurological impairment; GS type 2 (RAB27A gene) is the most

How is Griscelli syndrome inherited?

Griscelli syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Griscelli syndrome typically begin?

Typical onset of Griscelli syndrome is infantile. Age of onset can vary across affected individuals.

Which specialists treat Griscelli syndrome?

2 specialists and care centers treating Griscelli syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.